This is a working overview of rodent models, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
=== Gonadectomy === While it was often recommended that women with CAIS eventually undergo gonadectomy to mitigate cancer risk, there are differing opinions regarding the necessity and timing of gonadectomy. The risk of malignant germ cell tumors with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. However, only three cases of malignant germ cell tumors in prepubescent girls with CAIS have been reported in the last 100 years. The youngest of these children was 14 years old. Individuals with CAIS naturally go through puberty via the aromatization of testosterone into estrogens. Therefore, removal of the gonads will result in an individual requiring hormone replacement therapy. Gonadectomy is generally not recommended before puberty to allow for puberty to occur spontaneously. Some individuals with CAIS may choose to go on testosterone HRT rather than estrogen. Research suggests that testosterone is at least as beneficial as estrogen replacement therapy and possibly improves outcomes in certain areas of well-being. If gonadectomy is performed early, then puberty must be artificially induced using gradually increasing doses of estrogen. If gonadectomy is performed late, then puberty will occur on its own, due to the aromatization of testosterone into estrogen.
=== Pump pressure === Pumps vary in pressure capacity, but their performance is measured on their ability to yield a consistent and reproducible volumetric flow rate. Pressure may reach as high as 60 MPa (6000 lbf/in2), or about 600 atmospheres. Modern HPLC systems have been improved to work at much higher pressures, and therefore are able to use much smaller particle sizes in the columns (<2 μm). These "ultra high performance liquid chromatography" systems or UHPLCs, which could also be known as ultra high pressure chromatography systems, can work at up to 120 MPa (17,405 lbf/in2), or about 1200 atmospheres. The term "UPLC" is a trademark of the Waters Corporation, but is sometimes used to refer to the more general technique of UHPLC.
== Applications == Lysine carboxypeptidase is found within the plasma and is used to inactivate certain proteins; this functions to protect the body from potent molecules that may escape from tissues. The most well-studied protein that is inactivated by this enzyme is bradykinin (along with other kinins such as kallidin) which contributes to inflammation and blood pressure regulation. However, the primary way bradykinin is degraded is by angiotensin I converting enzyme (ACE). Lysine carboxypeptidase is still important nonetheless, especially if a patient is receiving ACE inhibitors to treat a condition. Kinins are most often autocrine or paracrine hormones and are thus often restricted in location. If too much of the hormone escapes into the blood and levels rise too high, this can have harmful effects on the body. Lysine carboxypeptidase prevents this from happening. This enzyme has also proven to be important in inactivating anaphylatoxins which are inflammation-inducing proteins used in immune responses. Similarly to kinins, harmful effects can occur if too much of these proteins accumulate in the blood. Other molecules that this enzyme is involved in modifying, and consequently regulating, include creatine kinase, hemoglobin, stromal cell-derived factor-1α (SDF-1α), plasminogen receptors, and enkephalins. The enzymatic interaction with creatine kinase releases one lysine from each of two subunits and modifies its function. With hemoglobin, it speeds up the dissociation of the tetramer into dimers and increases its oxygen affinity.
Starting in 1947, Spedding and Powell used displacement ion-exchange chromatography for the separation of the rare-earth elements. Additionally, they showed the ion-exchange separation of 14N and 15N isotopes in ammonia. At the start of the 1950s, Kraus and Nelson demonstrated the use of many analytical methods for metal ions dependent on their separation of their chloride, fluoride, nitrate or sulfate complexes by anion chromatography. Automatic in-line detection was progressively introduced from 1960 to 1980 as well as novel chromatographic methods for metal ion separations. A groundbreaking method by Small, Stevens and Bauman at Dow Chemical Co. unfolded the creation of the modern ion chromatography. Anions and cations could now be separated efficiently by a system of suppressed conductivity detection. In 1979, a method for anion chromatography with non-suppressed conductivity detection was introduced by Gjerde et al. Following it in 1980, was a similar method for cation chromatography. As a result, a period of extreme competition began within the IC market, with supporters for both suppressed and non-suppressed conductivity detection. This competition led to fast growth of new forms and the fast evolution of IC. A challenge that needs to be overcome in the future development of IC is the preparation of highly efficient monolithic ion-exchange columns and overcoming this challenge would be of great importance to the development of IC.
A migraine trigger is anything that increases the sensitivity of the brain to migraines. The activity of nerve cells and chemical signals in the brain is affected by genetic, environmental, and neurological factors which interact. Once physical and chemical stimuli exceed an individual's sensitivity threshold, further neurological changes can lead to increased activity in the pain pathway of the brain, with heightened blood flow and transmission of pain signals. Categories of potential migraine triggers include emotions, nutrition, sleep, hormones, weather, environmental factors (noise, smells, lights), and strenuous movement. Internal migraine triggers such as hormones, stress, disturbed sleep, and fasting affect the body's ability to maintain a stable state. External migraine triggers such as temperature, noises, and odors can change how the body reacts to sensory information. Air pollution, in particular nitrous oxide, carbon monoxide, and particulate matter, appears to increase migraine risk. Determining when something truly acts as a causal trigger, as opposed to being a symptom of already occurring changes in the brain, is an ongoing area of research. In some cases, factors reported as triggers, such as sensory sensitivities, food cravings, and mood changes, may instead be symptoms in the early (prodromal) phase of migraine. Relationships between triggers are complex and may be bidirectional.
Sources: en.wikipedia.org
Pharmacies and drug stores comprise establishments engaged in retailing prescription or nonprescription drugs and medicines, and other types of medical and orthopaedic goods. Regulated pharmacies may be based in a hospital or clinic or they may be privately operated, and are usually staffed by pharmacists, pharmacy technicians, and pharmacy aides.
Moreover, manual analysis of the proposed candidates and their MS/MS spectra was still necessary to verify structures, which requires laborious technical analysis. To enable larger scale screenings, the software will require more advanced compound filtering and candidate ranking. Overall, the system is intended to facilitate the identification of inhibitors for challenging enzymatic targets while reducing the amount of synthetic efforts required. Its potential applications include inhibitor discovery in both academic and industrial research settings.
Bats are the only mammals capable of sustained flight, as opposed to the gliding of flying squirrels, colugos and sugar gliders. The fastest bat, the Mexican free-tailed bat (Tadarida brasiliensis), can achieve a ground speed of 160 km/h (100 mph).
Each of the monologues deals with an aspect of the feminine experience, touching on matters such as sexual activity, love, rape, menstruation, female genital mutilation, masturbation, birth, orgasm, the various common names for the vagina, or simply as a physical aspect of the body. A recurring theme throughout the pieces is the vagina as a tool of female empowerment, and the ultimate embodiment of individuality.
Sources: en.wikipedia.org
For example, Gioja (current Gioia Tauro), was fortified with city walls reinforced by watchtowers to defend against incursions. Several Calabrian cities such as Palmi (where the Saracen Tower stands) and Reggio Calabria were fortified with towers. Despite the heavy taxation and the growth of baronial power, the population remained loyal to the sovereign, seen as a defender of the poor people against the abuses of the powerful. In 1647–1648, exasperated by the excessive tax burden, people in Catanzaro stormed the offices of the tax collectors (arrendatori). The governor intervened and had the leaders of the revolt hanged, causing the rest to flee.
=== Financial performance === GoodRx was founded in Santa Monica, California in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million), and 2019 ($66 million), but recorded a loss of $293.6 million in 2020 due to IPO-related expenses. In September 2020, GoodRx went public on the Nasdaq under the ticker symbol GDRX. The company priced its initial public offering at $33 per share, above the expected range of $24 to $28, raising more than $1.1 billion at an initial valuation of approximately $12.7 billion. In the first half of 2020, the company reported revenues of $257 million and net income of $55 million. GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. During the first half of 2021, the company's share price declined by 10.7%. The decline was attributed to increased competition in online pharmacy services and slower user growth. GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service. GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%.
60 amino acids in the extracellular N-terminal domain three transmembrane helices (TM1, 2, and 3) an intracellular loop of 46 amino acids connecting TM1 and TM2 a short intracellular C-terminal domain of 15 amino acids. The homotrimeric assembly is conserved across species, from plants, yeast to mammals.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.